Beta Bionics price target lowered to $25 from $33 at Goldman Sachs

Goldman Sachs analyst David Roman lowered the firm’s price target on Beta Bionics (BBNX) to $25 from $33 and keeps a Buy rating on the shares. The share selloff reflects concerns about slowing growth, uncertainty around insulin pump end-market health, and elevated expectations set by prior bullish commentary, the analyst tells investors in a research note. Looking ahead, upside to consensus remains possible, with key catalysts including a return to beat-and-raise quarters, clearer market-share trajectory, more detail on the Mint patch pump and bi-hormonal pipeline, and potential indication expansion into Type 2 intensive insulin patients, the firm says.